News & Videos - SIENNA BIOPHARMACEUTICALS INC.

WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of Delaware (the “Court”) entered an order approving Sienna’s proposed bidding procedures and Chapter 11 sale process timeline (the “Bidding Procedures Order”). 1 Under the Bidding Procedures Order, all bids to acquire all...

-- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 12, 2019, the Nasdaq Hearings Panel (the “Panel”) granted the Company’s request for continued listing on the Nasdaq Stock Market (“Nasdaq”), subject to certain conditions, including the...

WESTLAKE VILLAGE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for SNA-001, a topical pre-treatment to standard laser devices to remove unwanted light hair, and has received acknowledgement from FDA that the submission has been accepted. The purpose of the 510(k) notification is...

WESTLAKE VILLAGE, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code. “We believe this decision is in the best interests of Sienna and its stakeholders,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “The protections afforded by...

WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives to maximize shareholder value. With Cowen's assistance, Sienna will continue to explore capital raising to enable the initiation of its planned Phase 3 pivotal clinical trials for SNA-120...

WESTLAKE VILLAGE, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the BMO Capital Markets Prescriptions for Success Healthcare Conference, Tuesday, June 25, 2019, 1:40 p.m. ET, in New York. The presentation will be webcast live and can be accessed through the Investor...

-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the results of its recent Phase 2b clinical trial with SNA-120 (pegcantratinib), the Company’s Phase 3 topical, non-steroidal Tropomyosin receptor kinase A (TrkA) inhibitor under investigation for the treatment of...

WESTLAKE VILLAGE, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Paul F. Lizzul, M.D., Ph.D., Chief Medical Officer, and Silvio Traversa, B.Sc., Ph.D., Chief Scientific Officer, are scheduled to present at the Dermatology Drug Development Summit Europe, May 21-23, 2019, in Frankfurt, Germany. Dr. Lizzul also serves as the Summit’s Chair. About the Presentations Title: “Bridging the...

-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase 3 program in second half of 2019 WESTLAKE VILLAGE, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced biopsy data from its recent Phase 2b clinical trial with SNA-120 (pegcantratinib), the Company’s...

WESTLAKE VILLAGE, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Bank of America Merrill Lynch Health Care Conference 2019, Wednesday, May 15, 2019, 3:55 p.m. PDT, in Las Vegas. The presentation will be webcast live and can be accessed through the Investor Relations section of the Company’s website at...

-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019. “We are pleased to report the results of our first quarter,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “We completed a positive End-of-Phase 2 meeting with the U.S....

-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the promotion of Alexander Azoy to Chief Financial Officer (CFO). Mr. Azoy, who has served as Sienna’s Corporate Controller since December 2017, will succeed John W. Smither, who has resigned for personal reasons, effective April 1, 2019. “We are delighted to announce Alex’s...

WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018. “We are pleased to report the results of our 2018 fourth quarter and full year and contemplate the possibilities in 2019, particularly in light of our streamlined focus on strategic priorities and successful equity raise,” said Frederick C....

WESTLAKE VILLAGE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to present at the Cowen and Company 39 th Annual Health Care Conference, Monday, Mar. 11, 2019, 11:20 a.m. EDT, in Boston. The presentation will be webcast live and can be accessed through the Investor Relations section...

WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $2.50 per share. The gross proceeds to Sienna from the offering are expected to be $20.0 million, before underwriting discounts and commissions and estimated offering costs. Sienna has granted the underwriters a 30-day...

WESTLAKE VILLAGE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Sienna. In connection with this offering, Sienna expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered...

-- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solution of silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has potential to expand the $3 billion U.S. laser hair removal market as an effective option for light-haired consumers -- -- Sienna to seek strategic partner for SNA-001, and will continue to focus on Phase 3 development of SNA-120 for Psoriasis and Pruritus and its Topical by Design™ Platform --...

WESTLAKE VILLAGE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna®, is scheduled to present at the 6 th Annual Dermatology Summit, Sunday, Jan. 6, 2019, 3:20 p.m. PST, in San Francisco. Dr. Beddingfield is also scheduled to present at the 37 th Annual J.P. Morgan Healthcare Conference, Wednesday, Jan. 9, 2019, 11 a.m. PST, in San Francisco. The...

WESTLAKE VILLAGE, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to participate in a fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference, Wednesday, Dec. 12, 2018, 10:20 a.m. Eastern Time, in New York. The presentation will be...

-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle (statistically significant) -- Subjects achieved 58% improvement in itch from baseline on the I-NRS vs 55% with vehicle (not statistically significant) -- SNA-120 was well tolerated with few treatment-related adverse events -- Sienna also reported data from exploratory Phase 1/2 study of atopic...